Disc Medicine (IRON)

Executive Summary

Disc Medicine is a publicly traded biotechnology company (NASDAQ: IRON) focused on developing transformative therapies for hematologic diseases. Its pipeline centers on three key programs: DISC-0974, an anti-hemojuvelin antibody targeting hepcidin to treat anemia in myelofibrosis, chronic kidney disease (CKD), and inflammatory bowel disease (IBD); DISC-1459, an oral inhibitor of the enzyme protoporphyrinogen oxidase (PPOX) for erythropoietic protoporphyria (EPP), which is advancing in Phase 3; and DISC-3405, an oral inhibitor of TMPRSS6 for polycythemia vera (PV) and sickle cell disease (SCD), currently in Phase 1/2. The company's scientific approach addresses significant unmet needs in anemia and porphyria, with potential for first-in-class or best-in-class therapies. Recent catalysts include positive Phase 2 data for DISC-1459 in EPP, supporting a registrational Phase 3 trial now underway. With a strong cash position and multiple value-driving readouts expected over the next 12–18 months, Disc Medicine is positioned for potential regulatory submissions and partnerships. However, risks include clinical trial execution and competitive landscape in myelofibrosis and CKD anemia.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for DISC-0974 in myelofibrosis-associated anemia60% success
• Q1 2027Phase 3 top-line data for DISC-1459 in erythropoietic protoporphyria (EPP)75% success
• H2 2027Phase 1 data for DISC-3405 in sickle cell disease (SCD)50% success